CervoMed/EIP Pharma trial posts results for neflamapimod in Lewy body dementia
Results for the completed Phase 2b RewinD-LB study of neflamapimod in dementia with Lewy bodies were posted to ClinicalTrials.gov on September 3, 2026.
This week brought one update, tied to a completed study of neflamapimod in dementia with Lewy bodies (DLB).
- The Phase 2b "RewinD-LB" study (NCT05869669), sponsored by EIP Pharma Inc with collaborators including the National Institute on Aging, Worldwide Clinical Trials, and CervoMed, Inc., tested whether neflamapimod, a p38 alpha kinase inhibitor, can improve learning, problem solving, and memory loss in 159 participants with dementia with Lewy bodies.1 The study is listed as completed, with primary completion recorded as May 29, 2025 and study completion as June 16, 20251, and results were first posted on September 3, 2026. The primary outcome measured change in the Clinical Dementia Rating Scale - Sum of Boxes for neflamapimod-treated participants compared to placebo recipients over the 16-week blinded treatment period.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.